NTRA

NASDAQ Healthcare

Natera, Inc. - Common Stock

Diagnostics & Research

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

๐Ÿ“Š Market Data
Price$207.28
Volume946,666
Market Cap29.60B
Beta1.680
RSI (14-Day)53.3
200-Day MA$196.79
50-Day MA$202.00
52-Week High$256.36
52-Week Low$131.81
Forward P/E-305.57
Price / Book16.91
๐ŸŽฏ Investment Strategy Scores

NTRA scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
๐Ÿš€ Moon Shot 87/100โ–ฒ +2
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 51/100โ–ฒ +3
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 43/100โ–ผ -5
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿš€ Moon Shot (87/100) โ€” this strategy High growth potential (high beta + oversold).

Lowest fit among scored strategies: ๐Ÿ’ฐ Dividend Daddy (10/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find NTRA in your text

Paste any article, transcript, or post โ€” the tool will extract NTRA and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.